AR018891A1 - Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol - Google Patents

Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol

Info

Publication number
AR018891A1
AR018891A1 ARP990102934A ARP990102934A AR018891A1 AR 018891 A1 AR018891 A1 AR 018891A1 AR P990102934 A ARP990102934 A AR P990102934A AR P990102934 A ARP990102934 A AR P990102934A AR 018891 A1 AR018891 A1 AR 018891A1
Authority
AR
Argentina
Prior art keywords
beta
aerosol
pressurized
agonist drug
agonist
Prior art date
Application number
ARP990102934A
Other languages
English (en)
Original Assignee
Baker Norton Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharma filed Critical Baker Norton Pharma
Publication of AR018891A1 publication Critical patent/AR018891A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Abstract

Se provee entonces un inhalador presurizado de dosificacion medida que contenga una formulacion estable de un fármaco beta-agonista, que no requiera derefrigeracion y, además, una formulacion estable de un fármaco beta-agonista que resulte adecuada para ser utilizada en un aerosol y no requiera derefrigeracion. Un inhalador presurizado de dosificacion medida que presenta un contenedor equipado con una válvula de dosificacion y contieneuna formulacion en aerosol presurizada preparada a partir deuna composicion que comprende: un fármaco beta-agonista; al menos un propelente fluoroalcano: ymas del 5% en peso, con relacion al peso total de la formulacion en aerosol, de un disolvente capaz de solubilizar o disolver el fármaco beta-agonista.Un inhalador presurizado de dosificacion medida que presenta un contenedor equipado con una válvula de dosificacion y contiene una formulacion enaerosol presurizada preparada a partir de una composicion que comprende: partículas de un fármaco beta-agonista, al menos un propelente fluoroalcano: y unsurfactante capaz de formar una suspension de las partículas de fármaco beta-agonista. Una formulacion en aerosol adaptada para ser utilizada en un aerosolpresurizado, la cual se prepara a partir de una composicion que comprende:un fármaco beta-agonista; al menos un propelente fluoroalcano: y más del 5% enpeso, con relacion al peso total de la formulacion en aerosol, de un disolvente capaz de solubilizar o disolver el fármaco beta-agonista. Una formulacionen aerosol adaptada para ser utilizada en un aerosol presurizado, la cual se prepara a partir de una composicion que comprende: partículas de un fármacobeta-agonista; al menos un propelente fluoroalcano: y un surfactante capaz de formar una suspension de las partículas de fármaco beta-agonista. Lasformulaciones en aerosol son estables bajo condiciones de hasta 40*C y 75*C de humedad relativa durante al menos 4 semanas.
ARP990102934A 1998-06-19 1999-06-18 Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol AR018891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/099,779 US6451285B2 (en) 1998-06-19 1998-06-19 Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant

Publications (1)

Publication Number Publication Date
AR018891A1 true AR018891A1 (es) 2001-12-12

Family

ID=22276581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102934A AR018891A1 (es) 1998-06-19 1999-06-18 Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol

Country Status (23)

Country Link
US (2) US6451285B2 (es)
EP (2) EP1306082B1 (es)
JP (1) JP2002518100A (es)
KR (1) KR20010053025A (es)
CN (2) CN1154477C (es)
AR (1) AR018891A1 (es)
AT (2) ATE250409T1 (es)
AU (1) AU762927B2 (es)
BR (1) BR9912170A (es)
CA (1) CA2335303A1 (es)
CO (1) CO5031245A1 (es)
DE (2) DE69915144T2 (es)
DK (2) DK1306082T3 (es)
ES (2) ES2205848T3 (es)
HU (1) HUP0102468A3 (es)
IL (1) IL140340A0 (es)
NO (1) NO20006466L (es)
PL (1) PL345399A1 (es)
PT (2) PT1085856E (es)
RU (1) RU2214230C2 (es)
SK (1) SK19442000A3 (es)
WO (1) WO1999065460A2 (es)
ZA (1) ZA200007455B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
HU230804B1 (hu) 2000-05-22 2018-06-28 Chiesi Farmaceutici S.P.A Gyógyászati célú stabil aeroszol összetétel, inhalátor az aeroszol pontos adagolásához és eljárás ennek feltöltésére
US20030072717A1 (en) * 2001-02-23 2003-04-17 Vapotronics, Inc. Inhalation device having an optimized air flow path
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
ATE267591T1 (de) * 2001-07-02 2004-06-15 Chiesi Farma Spa Optimierte tobramycin-formulierung zur aerosolbildung
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln
JP2005523905A (ja) * 2002-03-01 2005-08-11 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ ホルモテロール（ｆｏｒｍｏｔｅｒｏｌ）超微細調合物
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
MXPA05001903A (es) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Composicion para inhalacion.
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US9463161B2 (en) * 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
US20120272951A1 (en) 2009-12-16 2012-11-01 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
GB201108039D0 (en) 2011-05-13 2011-06-29 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117621D0 (en) 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3383366B1 (en) 2015-12-04 2020-03-25 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN109715148A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
CN113288869A (zh) 2016-09-19 2021-08-24 墨西哥氟石股份公司 药物组合物
CN114515284A (zh) 2016-09-19 2022-05-20 墨西哥氟石股份公司 药物组合物
CN109464429B (zh) * 2018-12-13 2021-04-27 上海方予健康医药科技有限公司 一种吸入压力定量气雾剂药物组合物及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (es) 1957-01-31 1957-04-11
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
IL97065A (en) 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
WO1992000061A1 (en) 1990-06-29 1992-01-09 Fisons Plc Pressurised aerosol compositions
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
CA2094266C (en) 1990-10-18 1999-06-01 Robert K. Schultz Aerosol formulations of beclomethasone-17,21-dipropionate
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
WO1992022286A1 (en) 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
DE4123663A1 (de) 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
AU663906B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
NZ246421A (en) 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
JP3342484B2 (ja) 1991-12-18 2002-11-11 アストラ・アクチエボラーグ 新規な配合
ATE137666T1 (de) 1991-12-31 1996-05-15 Hoechst Ag Medizinische aerosolformulierung
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
NZ298169A (en) 1994-12-22 1999-09-29 Astra Ab Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant
DE4446891A1 (de) * 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
CA2273835A1 (en) 1996-12-04 1998-06-11 Bioglan Ireland (R & D) Limited Pharmaceutical compositions and devices for their administration
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol

Also Published As

Publication number Publication date
KR20010053025A (ko) 2001-06-25
DK1306082T3 (da) 2004-06-01
NO20006466L (no) 2001-02-16
BR9912170A (pt) 2001-10-23
EP1085856A2 (en) 2001-03-28
PT1306082E (pt) 2004-05-31
JP2002518100A (ja) 2002-06-25
DE69911602D1 (de) 2003-10-30
DK1085856T3 (da) 2003-12-08
WO1999065460A3 (en) 2000-04-27
CN1522692A (zh) 2004-08-25
ES2215153T3 (es) 2004-10-01
HUP0102468A3 (en) 2002-12-28
DE69915144D1 (de) 2004-04-01
HUP0102468A2 (hu) 2002-03-28
AU762927B2 (en) 2003-07-10
US20020018753A1 (en) 2002-02-14
CN1154477C (zh) 2004-06-23
CA2335303A1 (en) 1999-12-23
DE69915144T2 (de) 2004-12-09
CO5031245A1 (es) 2001-04-27
AU4825999A (en) 2000-01-05
EP1085856B1 (en) 2003-09-24
ATE260093T1 (de) 2004-03-15
ZA200007455B (en) 2002-06-13
SK19442000A3 (sk) 2001-09-11
ATE250409T1 (de) 2003-10-15
US20030077230A1 (en) 2003-04-24
EP1306082B1 (en) 2004-02-25
IL140340A0 (en) 2002-02-10
RU2214230C2 (ru) 2003-10-20
PL345399A1 (en) 2001-12-17
DE69911602T2 (de) 2004-07-01
CN1310611A (zh) 2001-08-29
ES2205848T3 (es) 2004-05-01
EP1306082A1 (en) 2003-05-02
WO1999065460A2 (en) 1999-12-23
NO20006466D0 (no) 2000-12-18
PT1085856E (pt) 2004-01-30
US6451285B2 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
AR018891A1 (es) Inhaladores presurizados de dosificacion medida y formulaciones farmaceuticas en aerosol
BR9916865A (pt) Composição farmacêutica em aerossol contendohfa 227 e hfa 134a
ES2199739T5 (es) Composiciones de aerosol.
Maggi et al. Influence of the moisture on the performance of a new dry powder inhaler
AR038643A1 (es) Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico
ATE521340T1 (de) Pharmazeutische formulierungen für trockenpulverinhalatoren in form von hartpellets
DE69205177T2 (de) Pharmazeutische Aerosolformulierung.
ES2472268T3 (es) Formulaciones de aerosol que comprenden fumarato de formoterol dihidratado, un propelente, etanol y opcionalmente un esteroide, en las que el fumarato de formoterol dihidratado tiene un contenido de agua del 4,8-4,28% en peso
DE60114571D1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
AR009231A1 (es) Formulaciones en aerosol de formoterol.
HU208398B (en) Process for producing pharmaceutical aerosol composition
ES2602314T3 (es) Medicamento inhalable que comprende tiotropio
HU226694B1 (en) Medicinal aerosol products containing ciclesonide
AR012480A1 (es) Una unidad de dosis farmaceutica que comprende tibolona, un metodo para elaborarla y el uso de un producto de almidon como vehiculo en unidades dedosis farmaceuticas que comprenden tibolona
CA2355651A1 (en) Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide
ITMI20001051A1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per il trattamento di patologie broncopolmonari
SE0402345D0 (sv) A metered medication dose
ITMI20010428A1 (it) Composizioni ad uso inalatorio a base di formoterolo
JP2004529108A5 (es)
FARR The physico-chemical basis of radiolabelling metered dose inhalers with 99mTc
ES2314469T3 (es) Formulacion farmaceutica en aerosol que comprende un hidrofluoroalcano y una ciclodextrina acilada.
TH31799A (th) ฟอร์มูเลชั่นที่เป็นแอโรซอลของโมเมทาโซนฟูโรเอทที่เป็นอิสระจากคลอโรฟลูออโรคาร์บอน
TH17960B (th) ฟอร์มูเลชั่นที่เป็นแอโรซอลของโมเมทาโซนฟูโรเอทที่เป็นอิสระจากคลอโรฟลูออโรคาร์บอน
TH13269A (th) สูตรผสมยาละอองลอยทางเภสัชซึ่งประกอบด้วยบีโคลเมธาโซนไดโพรพิโอเนท

Legal Events

Date Code Title Description
FA Abandonment or withdrawal